CM
JAZZ icon

Crestline Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Crestline Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,625
Closed -$1.06M – 332
2024
Q4 		$1.06M Sell
8,625
-15,795
-65% -$1.86M 0.04% 403
2024
Q3 		$2.72M Buy
+24,420
New +$2.68M 0.14% 156

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Crestline Management's JAZZ Position: Q1 2025 in Review

Crestline Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2025, closing a stake of 8,625 shares — an estimated $1.06M sold.

Crestline Management first reported a position in JAZZ in Q3 2024 and held it in 2 quarters. The position peaked at $2.72M in Q3 2024. 550 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

  • Crestline Management reported no remaining Jazz Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 8,625 Jazz Pharmaceuticals shares in Q1 2025, an estimated $1.06M.
  • Crestline Management first reported a position in Jazz Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Crestline Management's Jazz Pharmaceuticals position peaked at $2.72M in Q3 2024.
  • 550 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.